News and Trends 6 Dec 2022
Entact Bio launches with $81M to develop precision medicines
Entact Bio has raised $81 million in series A financing to advance its proprietary Encompass platform for developing enhancement-targeting chimeric (ENTAC) molecules. The round was co-led by Qiming Venture Partners USA and venBio Partners, with participation by new investors Abingworth, Brandon Capital, Janus Henderson Investors, Logos Capital, Surveyor Capital (a Citadel company), and WEHI (Walter […]